Home › NDC Lookup › RxCUI directory › RxCUI 2630729

Velmanase alfa-tycv 10 MG Injection — RxCUI 2630729

Name: Velmanase alfa-tycv 10 MG Injection (RxCUI 2630729)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2630729 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2630729

Official nameVelmanase alfa-tycv 10 MG Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped1

Package NDCs mapped3

Reported Medicaid activity (SDUD)105 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Velmanase alfa: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Alpha-mannosidosis is a rare inherited disease where your body doesn't make enough of an enzyme called alpha-mannosidase. Without it, sugar-containing waste products pile up inside...
What exactly is alpha-mannosidosis, and how does this medicine help?
Yes — velmanase alfa is given as an IV infusion, meaning it goes directly into a vein. You'll need to go to a clinic or infusion center for each dose, which is once a week. The inf...
How is this medicine given, and will I need to go somewhere special for it?

📖 Read our full Velmanase alfa guide →

🕸️ Concept Web — How Velmanase alfa-tycv 10 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Velmanase alfa-tycv 10 MG Injection RxCUI 2630729 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Velmanase alfa 2630725 IN
- Velmanase alfa-tycv 2630724 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Lamzede 2630730 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Velmanase alfa Injection 2630728 SCDF
- Velmanase alfa-tycv Injection 2649048 SCDFP
- Velmanase alfa Injectable Product 2630727 SCDG
- Velmanase alfa-tycv Injectable Product 2661288 SCDGP
- Velmanase alfa Injection [Lamzede] 2630733 SBDF
- Velmanase alfa-tycv Injection [Lamzede] 2655991 SBDFP
- Lamzede Injectable Product 2630732 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Velmanase alfa-tycv 10 MG 2630726 SCDC
- Velmanase alfa-tycv 10 MG Injection [Lamzede] 2630734 SBD
- Velmanase alfa-tycv 10 MG [Lamzede] 2630731 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Velmanase alfa-tycv 10 MG SCDC · 2630726
Velmanase alfa Injection SCDF · 2630728
Velmanase alfa-tycv Injection SCDFP · 2649048
Velmanase alfa Injectable Product SCDG · 2630727
Velmanase alfa-tycv Injectable Product SCDGP · 2661288

Brand-Name Concepts

Velmanase alfa-tycv 10 MG Injection [Lamzede] SBD · 2630734
Velmanase alfa-tycv 10 MG [Lamzede] SBDC · 2630731
Velmanase alfa Injection [Lamzede] SBDF · 2630733
Velmanase alfa-tycv Injection [Lamzede] SBDFP · 2655991
Lamzede Injectable Product SBDG · 2630732
Lamzede BN · 2630730

📦 FDA Products & Package NDCs

1 product · 3 package NDCs

3 package NDCs map to RxCUI 2630729 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
10122-0180-02	1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (...	Lamzede	Chiesi USA, Inc.	2023-03-01
10122-0180-05	5 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (...	Lamzede	Chiesi USA, Inc.	2023-03-01
10122-0180-10	10 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON...	Lamzede	Chiesi USA, Inc.	2023-03-01

Observed labelers: Chiesi USA, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J0217	Inj velmanase alfa-tycv 1 mg	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.